Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.

@article{Emerson2010DexlansoprazoleAP,
  title={Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.},
  author={Christopher R. Emerson and Nino Marzella},
  journal={Clinical therapeutics},
  year={2010},
  volume={32 9},
  pages={
          1578-96
        }
}
BACKGROUND Dexlansoprazole, the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. It is indicated for healing all grades of esophagitis, maintaining the healing of erosive esophagitis (EE), and treating heartburn associated with nonerosive gastroesophageal reflux disease. OBJECTIVE This article reviews the pharmacology, pharmacokinetics, and pharmacodynamics of dexlansoprazole, as well as its clinical efficacy and… Expand
19 Citations
Stereoselective and nonstereoselective pharmacokinetics of rabeprazole – an overview
  • 5
High and Frequent Dose of Dexlansoprazole and Amoxicillin Dual Therapy for Helicobacter pylori Infections: A Single Arm Prospective Study.
  • 9
  • PDF
Current Pharmacological Management of Gastroesophageal Reflux Disease
  • 31
  • PDF
...
1
2
...

References

SHOWING 1-10 OF 54 REFERENCES
Effectiveness of proton pump inhibitors in nonerosive reflux disease.
  • 398
Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis
  • 429
Review article: the unmet needs in delayed‐release proton‐pump inhibitor therapy in 2005
  • R. Hunt
  • Medicine
  • Alimentary pharmacology & therapeutics
  • 2005
  • 51
...
1
2
3
4
5
...